Showing 3571-3580 of 5621 results for "".
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- iCare Launches ST500 Slit-Lamp Based Tonometerhttps://modernod.com/news/icare-launches-st500-slit-lamp-based-tonometry/2482436/iCare announced the release of the iCare ST500, a slit-lamp-based tonometer that brings the features of iCare’s rebound tonometry technology into a modern design. The iCare ST500 offers an advanced solution for IOP measurement, combining extreme ease of u
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- Alcon Announces New Cataract Surgery Outcomes Data, Hosts Educational Program at ESCRShttps://modernod.com/news/alcon-announces-new-cataract-surgery-outcomes-data-hosts-educational-program-at-escrs/2482426/Alcon is set to unveil new scientific data at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, from September 6-10, 2024. The company will showcase its surgical ophthalmic products and equipment, highlighting innovations designed to optimize
- Oculus Unveils Pentacam Cornea OCThttps://modernod.com/news/oculus-unveils-pentacam-cornea-oct-at-escrs-2024/2482425/Oculus is introducing the Pentacam Cornea OCT, a tool that combines Scheimpflug technology with the world’s first pericentric OCT scanning system, according to a company news release. The device provides cornea specialists with imaging capabilities, capturing both Scheimpflug
- BlueRock Receives FDA Clearance for IND Application of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-receives-fda-clearance-for-ind-application-of-opct-001-for-primary-photoreceptor-diseases/2482422/Bayer subsidiary BlueRock Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to in
- Samsara Vision Promotes Jason Herod to Chief Commercial Officerhttps://modernod.com/news/samsara-vision-promotes-jason-herod-to-chief-commercial-officer/2482421/Samsara Vision announced that Jason Herod, formerly Vice President Commercial, International Markets, has been promoted to Chief Commercial Officer (CCO), effective August 15, 2024. Mr. Herod joined Samsara Vision in August 2021, bringing with him over 24 years of extensive experi
- Haag-Streit Introduces METIS Ophthalmic Microscope Systemhttps://modernod.com/news/haag-streit-unveils-metis-ophthalmic-microscope-system/2482418/Haag-Streit has introduced the METIS ophthalmic microscope system, which is designed to provide optical performance, ergonomic design, and advanced features tailored for precision and efficiency. Superior Optical Experience The METIS microscope integrates Haag